LFA-9 (mpges-1/5-LOX inhibitor): preclinical studies to support a clinical trial, POP 9/17/18-9/16/2020 (up to 9/17/2021 if all optional tasks exercised)

Ended Awarded Last action

Contract number
75N91018F00005
Awardee
Awarding agency
Obligated
$1,984,676

Award facts

Opportunity
Contract value 100% obligated
$1,984,675.73 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Chicago, IL 60616, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00013 -$96
Supplemental Agreement for work within scope P00012 $0
Supplemental Agreement for work within scope P00011 $0
Supplemental Agreement for work within scope P00010 $0
Supplemental Agreement for work within scope P00009 -$3,058
Supplemental Agreement for work within scope P00008 $39,250
Exercise an Option P00007 $418,720
Other Administrative Action P00006 $0
Exercise an Option P00005 $701,683
Change Order P00004 $24,931
Exercise an Option P00003 $117,558
Supplemental Agreement for work within scope P00002 · LFA(mpges-1/5-LOX inhibitor): preclinical studies to support a clinical trial, POP 9/17/18-9/16/2021 (up to 9/17/2022 if all optional tasks exercised) $0
Other Administrative Action P00001 $0
Original award $685,688
Show all 14

About this award

Written by GovTribe AI ·

The National Cancer Institute awarded a $1.98 million firm fixed-price delivery order to IIT Research Institute (IITRI) on September 17, 2018, for preclinical studies supporting clinical trial development of an MPGES-1/5-LOX inhibitor therapeutic candidate. The contract, which was ultimately completed by July 25, 2025, was performed at IITRI's Chicago, Illinois facility and encompassed toxicology and pharmacology testing services required to support investigational new drug applications and advance the candidate toward human clinical evaluation. This delivery order was issued under the PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) master IDIQ vehicle, which provides the National Cancer Institute with access to specialized preclinical research capabilities. The contract included a base period from September 17, 2018, through September 16, 2020, with potential extension through September 17, 2021, if optional tasks were exercised.

IITRI, a nonprofit contract research organization and subsidiary of the Illinois Institute of Technology, specializes in preclinical drug development services for federal agencies and has extensive experience conducting GLP and non-GLP toxicology studies in animal models to support therapeutic development across multiple disease areas. As a child entity of Illinois Institute of Technology, IITRI regularly supports the National Cancer Institute and other National Institutes of Health components through multiple IDIQ vehicles with combined potential values exceeding $500 million. No small business set-aside was utilized for this contract award.

Quick answers

Who was awarded contract 75N91018F00005?

75N91018F00005 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on September 17, 2018.

How much is contract 75N91018F00005 worth?

The government has obligated $1,984,676 on 75N91018F00005.

Is contract 75N91018F00005 an order under another contract?

Yes. 75N91018F00005 is a delivery order under HHSN261201500024I, an indefinite delivery contract, on PREVENT Toxicology and Pharmacology Testing (PREVENT TOX).

Was contract 75N91018F00005 competed?

The extent of competition for 75N91018F00005 was full and open competition. The government received 2 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login